Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase II Trial to Outline the Efficacy of Gemcitabine Containing Regimens (Gemcitabine/Carboplatin and Gemcitabine/Paclitaxel) When Used as Preoperative Chemotherapy In Patients With Stage I and II NSCLC

NCT00191256 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT00191256
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00191256 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase II Trial to Outline the Efficacy of Gemcitabine Containing Regimens (Gemcitabine/Carboplatin and Gemcitabine/Paclitaxel) When Used as Preoperative Chemotherapy In Patients With Stage I and II NSCLC
Lead sponsor
Eli Lilly and Company
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2001
Completion date
July 31, 2006
Enrollment
77
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, non small cell lung